

BMJ Open

Evaluation of prognostic utility of serum CRP levels in combination with CURB-65 and validation of the CURB-65 for prediction of mortality in patients with clinically suspected sepsis using decision curve analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-007049
Article Type:	Research
Date Submitted by the Author:	29-Oct-2014
Complete List of Authors:	Yamamoto, Shungo; School of Public Health in the Graduate School of Medicine, Kyoto University, Department of Healthcare Epidemiology; Kobe University Hospital, Division of Infectious Diseases Yamazaki, Shin; Kyoto University, Department of Healthcare Epidemiology Shimizu, Tsunehiro; Kyoto City Hospital, Department of Infectious Diseases Takeshima, Taro; Jichi Medical University, Division of Community and Family Medicine, Center for Community Medicine; Kyoto University, Department of Healthcare Epidemiology Fukuma, Shingo; Kyoto University, Department of Healthcare Epidemiology Yamamoto, Yosuke; Kyoto University, Department of Healthcare Epidemiology Tochitani, Kentaro; Kyoto City Hospital, Department of Infectious Diseases Tsuchido, Yasuhiro; Kyoto City Hospital, Department of Infectious Diseases Shinohara, Koh; National Center for Global Health and Medicine, Disease Control and Prevention Center Fukuhara, Shunichi; Kyoto University, Department of Healthcare Epidemiology
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Diagnostics, Emergency medicine, Medical management
Keywords:	PRIMARY CARE, STATISTICS & RESEARCH METHODS, INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

1
2
3
4 **Evaluation of prognostic utility of serum CRP levels in combination with CURB-65 and**
5
6 **validation of the CURB-65 for prediction of mortality in patients with clinically**
7
8 **suspected sepsis using decision curve analysis**
9
10

11
12
13
14 Shungo Yamamoto MD, DTM&H¹, Shin Yamazaki PhD¹, Tsunehiro Shimizu MD, PhD²,
15
16 Taro Takeshima MD^{1,3}, Shingo Fukuma MD, PhD^{1,5}, Yosuke Yamamoto MD, PhD¹, Kentaro
17
18 Tochitani MD², Yasuhiro Tsuchido MD², Koh Shinohara MD⁴, Shunichi Fukuhara MD,
19
20 DMSc^{1,5}
21
22
23
24
25

26
27 ¹Department of Healthcare Epidemiology, School of Public Health in the Graduate School of
28
29 Medicine, Kyoto University, Kyoto, Japan
30

31
32 ²Department of Infectious Diseases, Kyoto City Hospital, Kyoto, Japan
33

34
35 ³Division of Community and Family Medicine, Center for Community Medicine, Jichi
36
37 Medical University, Tochigi, Japan
38

39
40 ⁴Disease Control and Prevention Center, National Center for Global Health and Medicine,
41
42 Tokyo, Japan
43

44
45 ⁵Center for Innovative Research for Communities and Clinical Excellence (CIRC2LE),
46
47 Fukushima Medical University, Fukushima, Japan
48
49
50

51
52 **Corresponding author:**
53

54
55 Shunichi Fukuhara
56

57
58 Department of Healthcare Epidemiology
59
60

1
2
3 School of Public Health in the Graduate School of Medicine
4
5

6 Kyoto University
7

8 Yoshida Konoemachi
9

10 Sakyo-ku, Kyoto, 606 8501, Japan
11

12 E-mail: fukuhara.shunichi.6m@kyoto-u.ac.jp
13

14 Phone: +81-75-753-4646, Fax: +81-75-753-4644
15
16
17
18
19

20 21 **Conflict of interests** 22

23 All authors certify that they have no conflict of interests.
24
25
26
27
28

29 **Keywords:** CURB-65; CRP; sepsis; decision curve analysis; net benefit
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: The prognostic utility of serum C reactive protein (CRP) alone in sepsis is controversial. Here, we evaluated the prognostic utility of serum CRP levels in combination with the CURB-65 score.

Design: Retrospective cohort study.

Setting: Emergency department (ED) of an urban teaching hospital in Japan.

Participants: Consecutive ED patients over 15 years old who were admitted to the hospital after having a blood culture taken in the ED between 1st January 2010 and 31st December 2012.

Main outcome measures: 30-day in-hospital mortality.

Results: 1262 patients ultimately analyzed for score evaluation. The 30-day in-hospital mortality was 8%. Multivariable analysis showed that serum CRP ≥ 150 mg/L was an independent predictor of death (adjusted odds ratio: 1.8; 95% confidence interval [CI]: 1.1 to 2.8). We assessed the predictive performance of the CURB-65 as well as a modified CURB-65 with CRP (≥ 15 mg/dL) added. The area under the receiver operating characteristics curve (AUC) of the CURB-65 and modified CURB-65 were 0.76 (95% CI: 0.72 to 0.80) and 0.77 (95% CI: 0.72 to 0.81), respectively. Both models presented good calibration for mortality and were useful among threshold probabilities in the range of 0% to 30%. However, while incorporating CRP into CURB-65 yielded a significant category-free net reclassification improvement (NRI) of 0.387 (95% CI: 0.193 to 0.582) and integrated discrimination improvement (IDI) of 0.015 (95% CI: 0.004 to 0.027), decision curve analyses showed the CURB-65 and the modified CURB-65 scores had comparable net benefits for

1
2
3
4 prediction of mortality.

5
6 **Conclusions:** Measurement of serum CRP added limited clinical usefulness to the CURB-65
7
8 in predicting mortality in patients with clinically suspected sepsis, regardless of the source.
9

10
11
12
13
14 **Article summary:**

15
16 **Strengths and limitations of this study**

- 17
18
19 ● A major strength of this study is using decision curve analysis for evaluation of clinical
20 usefulness. That revealed the additive clinical usefulness of CRP to the CURB-65 was
21 limited, although reclassification metrics such as net reclassification improvement and
22 integrated discrimination improvement were improved.
23
24 ● The CURB-65 was validated in Asian population with clinically suspected infection,
25 regardless of the source, with adequate sample size as an external validation study. The
26 AUC was 0.76 (95%CI: 0.72 to 0.80) and it was useful among threshold probabilities in
27 the range of 0% to 30%. Our data enhanced the generalizability of the CURB-65 score.
28
29 ● The limitations of this study are the possibility of selection bias of the eligible patients
30 and the retrospective nature of the study in a single hospital.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Sepsis is a major cause of morbidity and mortality worldwide, with in-hospital mortality still at 18% or more, according to recent surveys in resource-rich countries.¹⁻³ Early identification of high-risk patients and timely intervention for sepsis are therefore crucial to improving outcomes.

Severity assessment is important in the management of patients, including decision-making regarding choice of treatment and patient disposition. To encourage implementation, a clinical prediction rule must be user-friendly.⁴ The CURB-65 is a simple prediction rule originally developed as a prognostic scoring system for community-acquired pneumonia (CAP).⁵ The rule has been well validated in patients with CAP, and CURB-65-guided antibiotic therapy has safely reduced broad-spectrum antibiotic use in this population.^{6 7} In addition to its utility among CAP patients, CURB-65 has also been correlated with mortality in patients with suspected sepsis, regardless of the source, and in patients admitted for non-surgical illness in the United States, Spain, and the United Kingdom;⁸⁻¹⁰ however, the system has not yet been validated in such populations in Asian countries. Serum C reactive protein (CRP) is an acute phase protein often evaluated as a marker of

systemic inflammation.¹¹ In Japan, serum CRP levels have been used as a diagnostic and prognostic marker of infection in daily clinical practice and clinical trials of new drugs.¹²

However, evidence demonstrating its value is insufficient at present for routine application of serum CRP levels to assess severity of infection. As a prognostic marker, some have reported that serum CRP on admission is associated with mortality.^{13 14} However, a systematic review reported conflicting findings, noting that serum CRP levels were not significantly different

1
2
3
4 between survivor and nonsurvivor, suggesting that these levels may have limited value in
5
6 reflecting the severity of sepsis.¹¹ As a diagnostic marker, the sensitivity and specificity of
7
8 serum CRP for discriminating bacterial from non-infectious inflammation was only 75% and
9
10 67%, respectively, according to a meta-analysis.¹⁵ However, while the diagnostic performance
11
12 of serum CRP alone is limited, serum CRP has been reported to contribute some additional
13
14 information to a prediction rule involving a patient's symptoms and physical examination in
15
16 diagnosis of pneumonia.¹⁶ In this respect, the additive prognostic value of serum CRP to an
17
18 existing severity score is unknown.
19
20
21
22
23

24 Here, we evaluated the prognostic performance of serum CRP in combination with the
25
26 CURB-65 score. In addition, we also validated the CURB-65 score in patients with suspected
27
28 sepsis, regardless of the source of infection, as a geographical and domain validation.⁵
29
30
31
32

33 **Materials and Methods**

34 *Study Design, Setting and Patients*

35
36 We performed a retrospective cohort study at Kyoto City Hospital, an urban teaching hospital
37
38 with 548 beds in Japan. Consecutive emergency department (ED) patients over 15 years old
39
40 admitted to the hospital after having a blood culture taken in the ED between 1 January 2010
41
42 and 31 December 2012 were included. Doctors' decision to order a blood culture was used as
43
44 a surrogate marker for suspected sepsis as in previous studies.^{10 17} To facilitate data
45
46 independence, only the index admission was included for patients with multiple admissions
47
48 during the study period. Patients transferred from another hospital or who had
49
50 cardiopulmonary arrest on arrival at the hospital were excluded.
51
52
53
54
55
56
57
58
59
60

Data collection

The following data were extracted from electronic medical records for each patient: age, gender, underlying disease, vital signs (heart rate, blood pressure, respiratory rate, mental confusion and body temperature), laboratory findings (white blood cell [WBC] count, platelet count, and blood urea nitrogen [BUN] and serum CRP levels), and outcome. For vital signs and laboratory data, initial values at the hospital visit were recorded. The items of the CURB-65 score were as follows: mental confusion (present/absent), BUN > 20 mg/dL (7 mmol/L), respiratory rate (RR) \geq 30/min, either or both systolic blood pressure (SBP) < 90 mmHg or diastolic blood pressure (DBP) \leq 60 mmHg, and age \geq 65 years.⁵ Mental confusion was defined as disorientation in person, place or time or being in a stupor or coma.⁵ We defined other covariates as follows: abnormal body temperature (BT) as > 38 or < 36 °C, tachycardia as heart rate (HR) > 90/min, leukocytosis as WBC > 15,000/ μ L, and low platelet count as platelet count < 150,000/ μ L, based on a previous study.¹⁷

The main outcome measure was 30-day in-hospital mortality. Patients who were discharged or transferred from the hospital within 30 days of admission or who remained in the hospital for more than 30 days were considered alive in this analysis.¹⁸

Statistical analysis

First, we explored the cut-off point of serum CRP level for prediction of death in patients with suspected sepsis. We graphically checked whether or not the relationship between serum CRP level and mortality was linear in the logit with a smoothing curve using a locally weighted

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

least squares (Lowess) regression.¹⁹ Because the optimal cut-off point was unknown, serum CRP results were first divided into quartiles and rounded to the nearest integer. Each patient was then assigned to one of four categories corresponding to the CRP quartiles. We conducted multivariable logistic regression analysis to adjust predictors of death by sequentially introducing pre-specified groups of variables, such as demographics, vital signs, laboratory findings and items of the CURB-65. We assessed multicollinearity using the variance inflation factor (VIF). VIFs greater than 2.5 may be problematic.²⁰ We also computed the unadjusted odds ratio of covariates using univariable logistic regression to show the influence of adjustment for predictors.

Second, we validated the CURB-65 model. We graphically assessed the calibration of the CURB-65 model with calibration plot and tested it with the Hosmer-Lemeshow test. A p value < 0.05 indicates a lack of good fit for the model. Regarding the model discrimination, we also computed the area under the receiver operating characteristic curve (AUC) with a 95% confidence interval (CI) using 500 bootstrap resampling.²¹ The predicted mortalities with 95% CI were calculated by introducing the CURB-65 score as a continuous variable into univariable logistic regression.

Third, we assessed the model performance of the modified CURB-65 score, which was made by incorporating CRP information into the CURB-65 model, using a calibration plot and Hosmer-Lemeshow test for calibration and AUC for discrimination. Additive information of CRP was evaluated by category-free net reclassification improvement (NRI) and integrated discrimination improvement (IDI).²² With regard to clinical usefulness, we examined the net benefit using decision curve analysis,²³ a novel method of evaluating diagnostic tests or

1
2
3
4 prediction models established by Vickers and Elkin. Briefly, the method is based on the
5
6 principle that the relative harms of false positives and false negatives can be expressed in
7
8 terms of a probability threshold.²⁴ The net benefit is obtained by subtracting the proportion of
9
10 patients who are false positive from the proportion who are true positive, weighting by the
11
12 relative harm of a false-positive and a false-negative result. The net benefit of making a
13
14 decision based on the model can be calculated with the following formula:
15
16
17
18
19
20

$$21 \quad \text{Net benefit} = \frac{\text{True Positives}}{n} - \left(\frac{P_t}{1-P_t}\right) \frac{\text{False positives}}{n}$$

22
23
24
25
26 where n is the total number of patients in the study and P_t is a given threshold probability.²³⁻²⁵
27
28

29
30 With regard to sample size estimation, at least 8 to 10 events per variable are required
31
32 for reliable multiple logistic regression analysis,^{26 27} and 100 events and 100 nonevents are
33
34 required for an external validation study.²⁸ We assumed 30 to 40 deaths per year among
35
36 eligible patients, collecting 3 years' worth of data (90 to 120 estimated deaths) to
37
38 appropriately conduct multiple logistic regressions with 11 variables and ensure adequate
39
40 statistical power.
41
42
43

44
45 In terms of handling missing values, we planned to perform a complete case analysis if
46
47 missing values were below 5%, as such an analysis might be feasible then.²⁹ If missing
48
49 values were above 5%, we planned to apply an appropriate imputation method.
50
51

52
53 Data were analyzed with R software 3.0.1 (www.r-project.org) and Stata software,
54
55 version 13 (StataCorp., College Station, TX, USA) including programs of Decision Curve
56
57 Analysis provided by Vickers.³⁰
58
59
60

Ethical approval

This protocol was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine and Kyoto City Hospital.

Results

Patient characteristics

Among 1310 eligible patients over 3 years of study, 108 deaths (8.2% mortality) were recorded. Demographics, underlying diseases, vital signs, laboratory findings and chief diagnosis for admission were presented in Table 1. Diagnosis was unclear in 96 patients (7.3%). Respiratory rates data were missing for 21 patients, and CRP data were missing for 28 (Table 2). Overall cases with any missing predictor were 48 (3.7%), so we conducted a complete case analysis, leaving 1262 patients (106 deaths, 8.4% mortality) for model evaluation analyses.

Evaluation of CRP as a predictor of mortality

The relationship between serum CRP level and mortality was almost linear in the logit. Serum CRP results were divided into quartiles and rounded to the nearest integer, and we set interim cut-off points as 20, 70, and 150 mg/L. Unadjusted odds ratios for mortality of each CRP group and other covariates are shown in Table 2. We set 150 mg/L as the cut-off point to dichotomize serum CRP levels and then sequentially introduced groups of variables into the multivariable logistic regression model.

1
2
3
4 Adjusted odds ratios for mortality are shown in Table 3. We found no evidence of
5
6 multicollinearity because the variance inflation factors for predictors in all models in Table 3
7
8 were less than 1.3. We identified serum CRP level ≥ 150 mg/L as an independent predictor of
9
10 death in patients with clinically suspected sepsis.
11
12

13 14 15 16 17 *Validation of the CURB-65*

18
19 Observed 30-day in-hospital mortalities and predicted mortalities computed by the CURB-65
20
21 score are shown in Table 4. The CURB-65 showed good calibration for mortality, with a
22
23 Hosmer-Lemeshow test of 4.08 (df=5, P=0.538), indicating good fit. The calibration plot is
24
25 shown in Supplementary Figure 1a. The AUC for the CURB-65 was 0.76 (95% CI: 0.72 to
26
27 0.80; Supplementary Figure 2).
28
29
30
31
32
33

34 35 36 37 *Additive information of CRP to CURB-65*

38
39 Because the adjusted odds ratio (i.e. regression coefficient) of CRP was comparable to each
40
41 item in the CURB-65, we made a modified CURB-65 score by adding one point to the
42
43 CURB-65 score when serum CRP level was ≥ 150 mg/L. Table 4 shows observed 30-day
44
45 in-hospital mortalities and predicted mortalities stratified by the modified CURB-65 score.
46
47 The modified CURB-65 also showed good calibration for mortality, with a
48
49 Hosmer-Lemeshow test of 4.52 (df=6, P=0.607). The calibration plot is shown in
50
51 Supplementary Figure 1b. The AUC for the modified CURB-65 was 0.77 (95% CI: 0.72 to
52
53 0.81; Supplementary Figure 2). By incorporating CRP into CURB-65, event NRI was -0.151
54
55 and nonevent NRI was 0.538, giving an overall category-free NRI of 0.387 (95% CI: 0.193 to
56
57
58
59
60

1
2
3
4 0.582, $p < 0.0001$). Further, IDI for events was 0.014 and IDI for nonevents was 0.001, giving
5
6 an overall IDI of 0.015 (95% CI: 0.004 to 0.027, $p < 0.01$). These findings were statistically
7
8 significant.
9

10 11 12 13 14 *Decision curve analysis*

15
16 Figure 1 demonstrates the decision curve for the CURB-65 and modified CURB-65 to predict
17
18 30-day in-hospital mortality in patients with clinically suspected sepsis. Both the CURB-65 and
19
20 the modified CURB-65 are useful between threshold probabilities of 0% to 30%. However,
21
22 both curves depict little difference in net benefit. The net benefits at each point of the CURB-65
23
24 score and the modified CURB-65 score are shown in Table 4. The summary of findings of this
25
26 study is presented in Table 5.
27
28
29
30
31
32
33
34
35

36 **Discussion**

37
38 We determined that having high CRP levels was independently associated with high mortality
39
40 in our population. We also conducted geographical and domain validation of the CURB-65 in
41
42 patients with clinically suspected sepsis, which comprised an external validation in a different
43
44 geographical area and in a population including different category of patients from CAP.⁴
45
46 Although reclassification metrics such as NRI and IDI were improved on incorporation of
47
48 CRP level, the additive clinical usefulness of CRP to the CURB-65 was admittedly limited
49
50 (Table 5).
51
52
53
54

55
56 The utility of serum CRP as a prognostic marker has been found to vary.¹¹ In Japan,
57
58
59
60

1
2
3
4 universal health coverage allows people to consult a doctor soon after they recognize any
5
6 symptoms, with no particular limitations.³¹ Given that secretion of CRP peaks at 36-50 h after
7
8 inflammatory stimulus,¹¹ serum CRP level might be useful as a surrogate marker of duration
9
10 from disease onset to consulting a doctor as well as a marker reflecting intensity of
11
12 inflammation. We believe that the association between serum CRP level and mortality will be
13
14 more easily identified in countries such as Japan where the population has easy access to
15
16 hospitals, due to the wide distribution in duration from disease onset to visiting a hospital.
17
18
19
20
21
22
23

24 **Strengths and limitations of the study**

25
26 A major strength of this study was our evaluation using decision curve analysis.
27
28 Performance of a prediction model has traditionally been evaluated by discrimination and
29
30 calibration. Discrimination is “a measure of how well a prognostic model discriminates
31
32 individuals with and without the outcome of interest” and calibration is “the ability to
33
34 correctly estimate the likelihood of a future event across the whole range of prognostic
35
36 estimates.”³² There is a tradeoff between discrimination and calibration, and a model typically
37
38 cannot be perfect with respect to both.^{33 34} Calibration is more relevant than discrimination
39
40 when estimating absolute risk of mortality in decision-making. However, having good
41
42 calibration alone is not sufficient to show that a model would improve decision-making.³⁵ As
43
44 metrics of reclassification, NRI and IDI have enjoyed increasing usage in evaluating
45
46 improvement in prediction models. However, these improvements in NRI and IDI are also not
47
48 sufficient for evaluating clinical usefulness.³⁶⁻³⁸ Decision curve analysis can take into account
49
50 risk threshold, weighting benefits and harms, and is useful in evaluating clinical utility of a
51
52
53
54
55
56
57
58
59
60

1
2
3
4 prediction model.^{23 38 39} For instance, the net benefit of 0.061 at a threshold probability of 3%
5
6 can be interpreted as meaning that making a decision based on the prediction model,
7
8 compared to assuming that all patients would be alive, leads to the equivalent of a net 6.1
9
10 true-positive results per 100 patients with no corresponding increase in the number of
11
12 false-positive results (Table 4).²³ Addition of CRP to the CURB-65 improved the prognostic
13
14 classification in terms of NRI and IDI; however, its clinical usefulness was limited when
15
16 considering net benefit examined by decision curve analysis.
17
18
19

20
21 Several limitations to the present study warrant mention. We cannot rule out the
22
23 possibility of selection bias, as only inpatients who had a blood culture taken were included.
24
25 We may therefore have missed patients with infection who did not undergo blood culture in
26
27 the ED, and contrarily, some patients without infection were included in the study. However,
28
29 clinicians must routinely make decisions in the ED despite being unsure as to whether or not
30
31 a patient is actually infected; we therefore considered it important to evaluate a clinical
32
33 prediction rule accounting for such clinical uncertainty. Inclusion of patients without
34
35 infectious diseases, we feel, reflects a real-world scenario. Another limitation is the
36
37 retrospective nature of the study and the fact that it was conducted in a single hospital. Given
38
39 the study's retrospective design, patients with high CRP might have received more intensive
40
41 therapy than those with relatively low CRP. Such bias might have lowered the predictive
42
43 ability of CRP. However, as an external validation study, we believe our data enhanced the
44
45 generalizability of the CURB-65 score with adequate statistical power.²⁸
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusions

The CURB-65 correlated well with 30-day in-hospital mortality in patients with clinically suspected infection, and it was useful among threshold probabilities in the range of 0% to 30%. While serum CRP level ≥ 150 mg/L was found to be associated with high mortality, its clinical usefulness in combination with the CURB-65 was limited. CURB-65 score may prove helpful in making decisions regarding the management of clinically suspected sepsis, regardless of the source.

Contributors

S. Yamamoto had full access to all of the data in the study and takes responsibility for integrity of the data and accuracy of the data analysis and wrote the first draft.

T. Shimizu, K. Tochitani, Y. Tsuchido and K. Shinohara collected and interpreted the data, and drafted the paper.

S. Yamazaki, T. Takeshima, S. Fukuma, Y. Yamamoto and S. Fukuhara supervised the research, interpreted the data and contributed to the writing of the manuscript.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None.

Ethics approval

The Ethics Committee of Kyoto University Graduate School and Faculty of Medicine and Kyoto City Hospital.

Data sharing statement

No additional data are available.

References

1. Kumar G, Kumar N, Taneja A, et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). *Chest* 2011;**140**:1223-31.
2. Kaukonen K-M, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. *JAMA* 2014;**311**:1308-16.
3. Fujishima S, Gando S, Saitoh D, et al. A multicenter, prospective evaluation of quality of care and mortality in Japan based on the Surviving Sepsis Campaign guidelines. *Journal of infection and chemotherapy* 2014;**20**:115-20.
4. Toll DB, Janssen KJM, Vergouwe Y, et al. Validation, updating and impact of clinical

- 1
2
3
4 prediction rules: a review. *Journal of clinical epidemiology* 2008;**61**:1085-94.
5
6
7 5. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia
8
9 severity on presentation to hospital: an international derivation and validation study.
10
11 *Thorax* 2003;**58**:377-82.
12
13
14 6. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting
15
16 mortality in hospitalised patients with community-acquired pneumonia. Systematic
17
18 review and meta-analysis. *Thorax* 2010;**65**:878-83.
19
20
21
22 7. Chalmers JD, Singanayagam A, Akram AR, et al. Safety and efficacy of CURB65-guided
23
24 antibiotic therapy in community-acquired pneumonia. *Journal of Antimicrobial*
25
26 *Chemotherapy* 2011;**66**:416-23.
27
28
29
30 8. Howell MD, Donnino MW, Talmor D, et al. Performance of severity of illness scoring
31
32 systems in emergency department patients with infection. *Academic emergency*
33
34 *medicine* 2007;**14**:709-14.
35
36
37
38 9. Armiñanzas C, Velasco L, Calvo N, et al. CURB-65 as an initial prognostic score in
39
40 *Internal Medicine patients*. *European journal of internal medicine* 2013;**24**:416-19.
41
42
43 10. Marwick CA, Guthrie B, Pringle JE, et al. Identifying which septic patients have
44
45 increased mortality risk using severity scores: a cohort study. *BMC anesthesiology*
46
47 *2014*;**14**:1.
48
49
50 11. Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious systemic
51
52 inflammatory response syndrome. *Clinica chimica acta* 2005;**351**:17-29.
53
54
55 12. Saito A, Miki F, Oizumi K, et al. Clinical evaluation methods for new antimicrobial
56
57 agents to treat respiratory infections: Report of the Committee for the Respiratory
58
59
60

- 1
2
3
4 System, Japan Society of Chemotherapy. *Journal of infection and chemotherapy*
5
6 1999;**5**:110-23.
7
8
9 13. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of
10
11 severity in community-acquired pneumonia. *The American journal of medicine*
12
13 2008;**121**:219-25.
14
15 14. Lobo SMA, Lobo FRM, Bota DP, et al. C-reactive protein levels correlate with mortality
16
17 and organ failure in critically ill patients. *Chest* 2003;**123**:2043-49.
18
19 15. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as
20
21 markers of bacterial infection: a systematic review and meta-analysis. *Clinical*
22
23 *infectious diseases* 2004;**39**:206-17.
24
25
26 16. van Vugt SF, Broekhuizen BDL, Lammens C, et al. Use of serum C reactive protein and
27
28 procalcitonin concentrations in addition to symptoms and signs to predict pneumonia
29
30 in patients presenting to primary care with acute cough: diagnostic study. *BMJ*
31
32 2013;**346**:f2450-f50.
33
34
35 17. Shapiro NI, Wolfe RE, Moore RB, et al. Mortality in Emergency Department Sepsis
36
37 (MEDS) score: a prospectively derived and validated clinical prediction rule. *Critical*
38
39 *Care Medicine* 2003;**31**:670-75.
40
41
42 18. Graham PL, Cook DA. Prediction of risk of death using 30-day outcome: a practical end
43
44 point for quality auditing in intensive care. *Chest* 2004;**125**:1458-66.
45
46
47 19. Hosmer DW. *Applied Logistic Regression*. 3 ed. Hoboken, New Jersey: Wiley, 2013.
48
49
50 20. Katz MH. *Multivariable Analysis: A Practical Guide for Clinicians and Public Health*
51
52 *Researchers*. 3rd ed. New York: Cambridge University Press, 2011.
53
54
55
56
57
58
59
60

- 1
2
3
4 21. Steyerberg EW, Bleeker SE, Moll HA, et al. Internal and external validation of predictive
5
6 models: a simulation study of bias and precision in small samples. *Journal of clinical*
7
8 *epidemiology* 2003;**56**:441-47.
9
10
11 22. Cook NR, Paynter NP. Performance of reclassification statistics in comparing risk
12
13 prediction models. *Biometrical journal* 2011;**53**:237-58.
14
15 23. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction
16
17 models. *Medical decision making* 2006;**26**:565-74.
18
19
20 24. Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a novel
21
22 method for evaluating diagnostic tests, prediction models and molecular markers.
23
24 *BMC medical informatics and decision making* 2008;**8**:53.
25
26
27 25. Vickers AJ. Decision analysis for the evaluation of diagnostic tests, prediction models and
28
29 molecular markers. *The American statistician* 2008;**62**:314-20.
30
31
32 26. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per
33
34 variable in logistic regression analysis. *Journal of clinical epidemiology*
35
36 1996;**49**:1373-79.
37
38
39 27. Cepeda MS, Boston R, Farrar JT, et al. Comparison of logistic regression versus
40
41 propensity score when the number of events is low and there are multiple confounders.
42
43 *American journal of epidemiology* 2003;**158**:280-87.
44
45
46 28. Vergouwe Y, Steyerberg EW, Eijkemans MJC, et al. Substantial effective sample sizes
47
48 were required for external validation studies of predictive logistic regression models.
49
50 *Journal of clinical epidemiology* 2005;**58**:475-83.
51
52
53 29. Royston P, Moons KGM, Altman DG, et al. Prognosis and prognostic research:
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Developing a prognostic model. *BMJ* 2009;**338**:b604.
30. Vickers AJ. Decision Curve Analysis. 2013.
<http://www.mskcc.org/research/epidemiology-biostatistics/health-outcomes/decision-curve-analysis-0>. Accessed 19 April, 2014.
31. Ikegami N, Yoo B-K, Hashimoto H, et al. Japanese universal health coverage: evolution, achievements, and challenges. *Lancet* 2011;**378**:1106-15.
32. Tripepi G, Jager KJ, Dekker FW, et al. Statistical methods for the assessment of prognostic biomarkers(part II): calibration and re-classification. *Nephrology Dialysis Transplantation* 2010;**25**:1402-05.
33. Cook NR. Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction. *Circulation* 2007;**115**:928-35.
34. Jiang X, Menon A, Wang S, et al. Doubly Optimized Calibrated Support Vector Machine (DOC-SVM): an algorithm for joint optimization of discrimination and calibration. *PLoS ONE* 2012;**7**:e48823.
35. Holmberg L, Vickers A. Evaluation of prediction models for decision-making: beyond calibration and discrimination. *PLoS Medicine* 2013;**10**:e1001491.
36. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology (Cambridge, Mass)* 2010;**21**:128-38.
37. Leening MJG, Vedder MM, Wittteman JCM, et al. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. *Annals of internal medicine* 2014;**160**:122-31.

1
2
3
4 38. Vickers AJ, Pepe M. Does the net reclassification improvement help us evaluate models
5
6 and markers? *Annals of internal medicine* 2014;**160**:136-37.
7

8
9 39. Localio AR, Goodman S. Beyond the usual prediction accuracy metrics: reporting results
10
11 for clinical decision making. *Annals of internal medicine* 2012;**157**:294-95.
12
13

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Patient characteristics, chief diagnosis for admission, and outcome

Characteristics	n=1310*
Demographics	
<i>Age (years), median (range)</i>	76 (15-100)
<i>Female, n (%)</i>	588 (44.9)
<i>Nursing home resident, n (%)</i>	37 (2.8)
Underlying diseases, n (%)	
<i>Cerebrovascular disease</i>	164 (12.5)
<i>Congestive heart failure</i>	106 (8.1)
<i>Chronic respiratory disease</i>	159 (12.1)
<i>Chronic kidney disease</i>	107 (8.2)
<i>Chronic liver disease</i>	80 (6.1)
<i>Diabetes mellitus</i>	252 (19.2)
<i>Malignancy</i>	230 (17.6)
<i>Dementia</i>	125 (9.5)
<i>Autoimmune disorder</i>	60 (5.0)
<i>Human immunodeficiency virus positive</i>	3 (0.2)
Vital signs	
<i>Heart rate (beats/min), median (SD)</i>	98 (20.4)
<i>Systolic blood pressure (mmHg), median (SD)</i>	132 (28.3)
<i>Respiratory rate (breaths/min), median (SD)</i>	20 (6.7)
<i>Body temperature (°C), median (SD)</i>	38.1 (1.4)
<i>Mental confusion, n (%)</i>	223 (17.0)
Laboratory data	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

White blood cell count ($/\mu L$), median (SD)	10400 (6503)
Platelet count ($\times 10^4/\mu L$), median (SD)	19.6 (9.9)
C reactive protein (mg/L), median (SD)	72.3 (90)
Blood urea nitrogen (mg/dL), median (SD)	19.3 (19.5)
Chief diagnosis for admission	
Pneumonia	405 (30.9)
Urinary tract infection	196 (15.0)
Skin and Soft tissue infection	69 (5.3)
Acute cholangitis	48 (3.7)
Acute cholecystitis	34 (2.6)
Bowel perforation	21 (1.6)
Other bacterial infection	154 (11.8)
Non-bacterial infection	94 (7.2)
Non-infection	193 (14.7)
Unclear	96 (7.3)
Bacteremia, n (%)	217 (16.6)
30-day in-hospital mortality, n (%)	108 (8.2)

Abbreviation: SD, standard deviation

*48 were excluded due to missing predictors in analyses for score evaluation.

Table 2. Unadjusted odds ratios for mortality calculated by univariable logistic regression

Variables	Unadjusted Odds Ratio (95% CI)	Missing n, (%)
CRP		
0.1-19.9 mg/L	1 [reference]	
20-69.9 mg/L	1.7 (0.8-3.5)	28 (2.1)
70-149.9 mg/L	2.3 (1.2-4.5)	
≥ 150 mg/L	4.1 (2.1-7.7)	
Age ≥ 65 years old	3.5 (1.9-6.6)	0 (0)
Female	0.6 (0.4-0.9)	0 (0)
Mental confusion	3.0 (2.0-4.6)	0 (0)
Hypotension (SBP < 90 or DBP ≤ 60 mmHg)	3.0 (2.0-4.5)	0 (0)
Abnormal body temperature (BT >38 or < 36 °C)	0.9 (0.6-1.3)	0 (0)
Tachycardia (HR > 90 /min)	1.5 (0.97-2.3)	0 (0)
Tachypnea (RR ≥ 30 /min)	3.2 (2.1-5.0)	21 (1.6)
Platelet count < 15 × 10⁴/μL	2.1 (1.4-3.1)	0 (0)
BUN > 20 mg/dL	4.8 (3.0-7.8)	0 (0)
WBC > 15000/μL	1.7 (1.1-2.6)	0 (0)
Overall	-	48 (3.7)

Abbreviation: CRP, C reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; BT, body temperature; HR, heart rate; RR, respiratory rate; BUN, blood urea nitrogen; WBC, white blood cell count

Table 3. Adjusted odds ratios for mortality in multivariable logistic regression analyses

Variables	Adjusted Odds Ratios (95% CI)				
	Model 1	Model 2	Model 3	Model 4	Model 5
CRP ≥ 150 mg/L	2.5 (1.6-3.7)	2.3 (1.5-3.5)	2.1 (1.4-3.3)	1.8 (1.1-2.8)	2.0 (1.3-3.1)
Age ≥ 65 years	-	3.7 (1.9-7.2)	3.0 (1.5-5.9)	2.5 (1.3-5.1)	2.3 (1.1-4.6)
Female	-	0.6 (0.4-0.9)	0.6 (0.4-0.9)	0.6 (0.4-1.02)	-
Mental confusion	-	-	2.4 (1.5-3.8)	2.1 (1.3-3.3)	2.1 (1.3-3.4)
Hypotension (SBP < 90 or DBP ≤ 60 mmHg)	-	-	2.7 (1.7-4.1)	2.3 (1.5-3.5)	2.1 (1.3-3.2)
Abnormal body temperature (BT >38 or < 36 °C)	-	-	1.0 (0.6-1.5)	1.0 (0.7-1.6)	-
Tachycardia (HR > 90/min)	-	-	1.4 (0.9-2.3)	1.5 (0.9-2.5)	-
Tachypnea (RR ≥ 30/min)	-	-	2.4 (1.5-3.9)	2.3 (1.4-3.7)	2.4 (1.5-3.9)
Platelet count < 15 × 10⁴/μL	-	-	-	1.8 (1.1-2.8)	-
BUN > 20 mg/dL	-	-	-	2.4 (1.4-4.0)	2.7 (1.6-4.5)
WBC > 15000/μL	-	-	-	1.5 (0.9-2.4)	-

Abbreviation: CRP, C reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; BT, body temperature; HR, heart rate; RR, respiratory rate; BUN, blood urea nitrogen; WBC, white blood cell count

Model 1: Unadjusted

Model 2: Adjusted for age and gender

Model 3: Adjusted for age, gender, and vital signs

Model 4: Adjusted for age, gender, vital signs, and lab data

Model 5: Adjusted for items of the CURB-65

Table 4. Observed mortality, predicted mortality, and net benefit in the CURB-65 and the modified CURB-65*

CURB-65 score	Observed 30-day mortality, % (death/total)	Predicted mortality [†] (95% CI) %	Net benefit [‡]	Modified CURB-65 score	Observed 30-day mortality, % (death/total)	Predicted mortality [†] (95% CI) %	Net benefit [‡]
0	0 (0/190)	1 (0.7-2.1)	0.075	0	0 (0/152)	1 (0.6-2.0)	0.075
1	3 (9/334)	3 (2.0-4.2)	0.061	1	2 (7/287)	2 (1.6-3.6)	0.068
2	8 (33/409)	7 (5.2-8.3)	0.034	2	6 (23/381)	5 (4.0-6.9)	0.048
3	13 (34/254)	14 (11.9-17.2)	0.015	3	12 (32/265)	11 (9.2-13.3)	0.024
4	30 (25/84)	28 (22.5-35.2)	0.004	4	17 (22/129)	22 (17.7-26.5)	0.012
5	39 (7/18)	48 (37.0-60.1)	0	5	44 (18/41)	38 (29.9-47.8)	0.005
				6	57 (4/7)	58 (45.2-70.4)	0

* The modified CURB-65 score was made by addition of 1 point if CRP \geq 150 mg/L.

[†] Predicted mortality was calculated by introducing the CURB-65 and modified CURB-65 score as a continuous variable into univariable logistic regression.

[‡] Net benefits were calculated for each predicted mortality as a threshold probability.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 5. Summary of findings of this study

	CURB-65	Modified CURB-65
Discrimination AUC	0.76 (95% CI: 0.72 to 0.80)	0.77 (95% CI: 0.72 to 0.81)
Calibration Hosmer-Lemeshow test and calibration plot	good	good
Reclassification Overall category-free NRI Overall IDI	0.387 (95% CI: 0.193 to 0.582, p<0.0001) 0.015 (95% CI: 0.004 to 0.027, p<0.01)	
Clinical usefulness NB examined by DCA	comparable	


Abbreviation: AUC, area under the receiver operating characteristic curve; NRI, net reclassification improvement; IDI, integrated discrimination improvement; NB, net benefit; DCA, decision curve analysis

Figure 1. Decision curve for the CURB-65 and modified CURB-65 (mCURB-65) to predict 30-day mortality in patients with suspected sepsis




The thick black line is the net benefit of treating no patients, assuming that all would be alive; the thin grey line is the net benefit of treating all patients similarly regardless of their severity, assuming that all would die; the long dashed line is the net benefit of treating patients according to the CURB-65 score; and the thin black line is the net benefit of treating patients based on the modified CURB-65 score.


Supplementary Figure 1a. Calibration plot of the CURB-65



Supplementary Figure 1b. Calibration plot of the modified CURB-65



Supplementary Figure 2. The receiver operating characteristics curves of the CURB-65 and the modified CURB-65



BMJ Open: first published as 10.1136/bmjopen-2014-007049 on 28 April 2015. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

view only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract [Within the method section of the abstract page 3] (b) Provide in the abstract an informative and balanced summary of what was done and what was found [See results section of abstract page 3-4]
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported [page 5-6]
Objectives	3	State specific objectives, including any prespecified hypotheses [page 6]
Methods		
Study design	4	Present key elements of study design early in the paper [Methods page 6-7]
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection [Methods page 6-7]
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up [Methods page 6-7] <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls [N/A] <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants [N/A] (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed [N/A] <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case [N/A]
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable [page 7]
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group [page 7]
Bias	9	Describe any efforts to address potential sources of bias [page 6-7]
Study size	10	Explain how the study size was arrived at [page 9]
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why [page 7]
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding [page 7-9] (b) Describe any methods used to examine subgroups and interactions [N/A] (c) Explain how missing data were addressed [page 9] (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed [page 7] <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed [N/A] <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy [N/A] (e) Describe any sensitivity analyses [N/A]

Continued on next page

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed [page 10 and table 1] (b) Give reasons for non-participation at each stage [N/A] (c) Consider use of a flow diagram [N/A information in page 10 and table 1]
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders [page 10 and table 1] (b) Indicate number of participants with missing data for each variable of interest [table 2] (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) [page 10]
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time [page 10 and table 1] <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure [N/A] <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures [N/A]
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included [page 10-11; table 2 and 3] (b) Report category boundaries when continuous variables were categorized [page 10-11; table 2] (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period [N/A]
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses [decision curve analysis in page 11-12; table 4; figure 1]

Discussion

Key results	18	Summarise key results with reference to study objectives [page 12]
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias [page 14]
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence [page 14-15]
Generalisability	21	Discuss the generalisability (external validity) of the study results [page 14]

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based [N/A]
---------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prognostic utility of serum CRP levels in combination with CURB-65 in patients with clinically suspected sepsis; decision curve analysis

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-007049.R1
Article Type:	Research
Date Submitted by the Author:	24-Mar-2015
Complete List of Authors:	Yamamoto, Shungo; School of Public Health in the Graduate School of Medicine, Kyoto University, Department of Healthcare Epidemiology; Kobe University Hospital, Division of Infectious Diseases Yamazaki, Shin; Kyoto University, Department of Healthcare Epidemiology Shimizu, Tsunehiro; Kyoto City Hospital, Department of Infectious Diseases Takeshima, Taro; Kyoto University, Department of Healthcare Epidemiology; Jichi Medical University, Division of Community and Family Medicine, Center for Community Medicine Fukuma, Shingo; Kyoto University, Department of Healthcare Epidemiology Yamamoto, Yosuke; Kyoto University, Department of Healthcare Epidemiology Tochitani, Kentaro; Kyoto City Hospital, Department of Infectious Diseases Tsuchido, Yasuhiro; Kyoto City Hospital, Department of Infectious Diseases Shinohara, Koh; National Center for Global Health and Medicine, Disease Control and Prevention Center Fukuhara, Shunichi; Kyoto University, Department of Healthcare Epidemiology
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Diagnostics, Emergency medicine, Medical management
Keywords:	PRIMARY CARE, STATISTICS & RESEARCH METHODS, INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts

1
2
3
4
5
6 **Prognostic utility of serum CRP levels in combination with CURB-65 in patients**
7
8
9 **with clinically suspected sepsis; decision curve analysis**
10
11
12
13
14

15 Shungo Yamamoto MD, DTM&H¹, Shin Yamazaki PhD¹, Tsunehiro Shimizu MD,
16 PhD², Taro Takeshima MD^{1,3}, Shingo Fukuma MD, PhD^{1,5}, Yosuke Yamamoto MD,
17
18 PhD¹, Kentaro Tochitani MD², Yasuhiro Tsuchido MD², Koh Shinohara MD⁴, Shunichi
19
20 Fukuhara MD, DMSc^{1,5}
21
22
23
24
25
26
27
28
29
30
31

32 ¹Department of Healthcare Epidemiology, School of Public Health in the Graduate
33
34 School of Medicine, Kyoto University, Kyoto, Japan
35
36

37
38 ²Department of Infectious Diseases, Kyoto City Hospital, Kyoto, Japan
39
40

41
42 ³Division of Community and Family Medicine, Center for Community Medicine, Jichi
43
44 Medical University, Tochigi, Japan
45
46

47
48 ⁴Disease Control and Prevention Center, National Center for Global Health and
49
50 Medicine, Tokyo, Japan
51
52

53
54 ⁵Center for Innovative Research for Communities and Clinical Excellence (CIRC2LE),
55
56
57
58
59
60

1
2
3
4
5
6 Fukushima Medical University, Fukushima, Japan
7
8
9

10
11
12 **Corresponding author:**
13

14 Shunichi Fukuhara
15

16
17 Department of Healthcare Epidemiology
18

19 School of Public Health in the Graduate School of Medicine
20

21
22 Kyoto University
23

24
25 Yoshida Konoemachi
26

27
28 Sakyo-ku, Kyoto, 606 8501, Japan
29

30
31 E-mail: fukuhara.shunichi.6m@kyoto-u.ac.jp
32

33
34 Phone: +81-75-753-4646, Fax: +81-75-753-4644
35
36
37
38
39
40
41
42
43
44

45 **Conflict of interests**
46

47 All authors certify that they have no conflict of interests.
48
49

50
51
52
53
54 **Keywords:** CURB-65; CRP; sepsis; decision curve analysis; net benefit
55
56
57
58
59
60

Abstract

Objectives: The prognostic utility of serum C reactive protein (CRP) alone in sepsis is controversial. We used decision curve analysis (DCA) to evaluate the clinical usefulness of combining serum CRP levels with the CURB-65 score in patients with suspected sepsis.

Design: Retrospective cohort study.

Setting: Emergency department (ED) of an urban teaching hospital in Japan.

Participants: Consecutive ED patients over 15 years old who were admitted to the hospital after having a blood culture taken in the ED between 1 January 2010 and 31 December 2012.

Main outcome measures: 30-day in-hospital mortality.

Results: Data from 1262 patients were analyzed for score evaluation. The 30-day in-hospital mortality was 8.4%. Multivariable analysis showed that serum CRP ≥ 150 mg/L was an independent predictor of death (adjusted odds ratio: 2.0; 95% confidence interval [CI]: 1.3 to 3.1). We compared the predictive performance of the CURB-65 with the performance of a modified CURB-65 with that included CRP (≥ 150 mg/L) to

1
2
3
4
5
6 quantify the clinical usefulness of combining serum CRP to the CURB-65. The areas
7
8
9
10 under the receiver operating characteristics curves (AUC) of the CURB-65 and
11
12 modified CURB-65 were 0.76 (95% CI: 0.72 to 0.80) and 0.77 (95% CI: 0.72 to 0.81),
13
14 respectively. Both models had good calibration for mortality and were useful among
15
16 threshold probabilities from 0% to 30%. However, while incorporating CRP into
17
18 CURB-65 yielded a significant category-free net reclassification improvement of 0.387
19
20 (95% CI: 0.193 to 0.582) and integrated discrimination improvement of 0.015 (95% CI:
21
22 0.004 to 0.027), DCA showed that the CURB-65 and the modified CURB-65 score had
23
24 comparable net benefits for prediction of mortality.
25
26
27
28
29
30
31
32
33
34

35 **Conclusions:** Measurement of serum CRP added limited clinical usefulness to the
36
37 CURB-65 in predicting mortality in patients with clinically suspected sepsis, regardless
38
39 of the source.
40
41
42
43
44
45
46
47

48 **Article summary:**

49
50 **Strengths and limitations of this study**

- 51
52
53
54
55 ● Combining serum CRP with the CURB-65 gave statistically significant values of
56
57
58
59
60

1
2
3
4
5
6 net reclassification improvement and integrated discrimination improvement. In
7
8
9
10 contrast, decision curve analysis showed that combining serum CRP with the
11
12
13 CURB-65 was of only limited clinical usefulness.

- 14
15
16 ● The limitations of this study are the possibility of selection bias of the eligible
17
18
19 patients and the retrospective nature of the study in a single hospital.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Sepsis is a major cause of morbidity and mortality worldwide, with in-hospital mortality still at 18% or more, according to recent surveys in resource-rich countries.¹⁻³ Early identification of high-risk patients and timely intervention for sepsis are therefore crucial to improving outcomes.

Severity assessment is important in the management of patients, including decision-making regarding choice of treatment and patient disposition. To encourage implementation, a clinical prediction rule must be user-friendly.⁴ While there are a lot of well-known scoring systems for severity of illness such as the Acute Physiology and Chronic Health Evaluation (APACHE), Sepsis-related Organ Failure Assessment (SOFA), and Multiple Organ Dysfunction Score (MODS), they have too many items to use conveniently in the emergency department (ED).⁵ In addition, these scores have not been well validated in settings other than the intensive care unit (ICU). The CURB-65 is a simple prediction rule originally developed as a prognostic scoring system for community-acquired pneumonia (CAP).⁶ The rule has been well validated in patients with CAP, and CURB-65-guided antibiotic therapy has safely reduced broad-spectrum

1
2
3
4
5
6 antibiotic use in this population.^{7 8} In addition to its utility among CAP patients,
7
8
9
10 CURB-65 has also been correlated with mortality in patients with suspected sepsis,
11
12
13 regardless of the source, and in patients admitted for non-surgical illness.⁹⁻¹¹
14

15
16 Serum C reactive protein (CRP) is an acute phase protein often evaluated as a
17
18 marker of systemic inflammation.¹² In Japan, serum CRP levels have been used as a
19
20
21
22 diagnostic and prognostic marker of infection in daily clinical practice and clinical trials
23
24
25 of new drugs.¹³ However, evidence demonstrating its value is insufficient at present for
26
27
28
29 routine application of serum CRP levels to assess severity of infection. As a prognostic
30
31
32 marker, some have reported that serum CRP on admission is associated with mortality.¹⁴
33

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
15 However, a systematic review reported conflicting findings, noting that serum CRP
levels were not significantly different between survivor and nonsurvivor, suggesting that
these levels may have limited value in reflecting the severity of sepsis.¹² As a diagnostic
marker, the sensitivity and specificity of serum CRP for discriminating bacterial from
non-infectious inflammation was only 75% and 67%, respectively, according to a
meta-analysis.¹⁶ However, while the diagnostic performance of serum CRP alone is
limited, serum CRP has been reported to contribute some additional information to a

1
2
3
4
5
6 prediction rule involving a patient's symptoms and physical examination in diagnosis of
7
8
9 pneumonia.¹⁷ In this respect, the additive prognostic value of serum CRP to an existing
10
11
12 severity score is unknown.
13

14
15 Performance of a prediction model has traditionally been evaluated by
16
17 discrimination and calibration. However, having good discrimination and calibration
18
19 alone is not sufficient to show that a model would improve decision-making.¹⁸ As
20
21 metrics of reclassification, net reclassification improvement (NRI) and integrated
22
23 discrimination improvement (IDI) have enjoyed increasing usage in evaluating
24
25 improvement in prediction models. However, these improvements quantified as NRI
26
27 and IDI are also not sufficient for evaluating clinical usefulness.¹⁹⁻²¹ Decision curve
28
29 analysis (DCA), which was first described by Vickers and Elkin, can be used to
30
31 incorporate the clinical consequences of a decision into evaluations of diagnostic tests
32
33 or prediction models.²² To our knowledge, there have been no studies in which DCA is
34
35 employed to evaluate the clinical usefulness of serum CRP levels and CURB-65 score
36
37 in patients with suspected sepsis.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53
54 Here, our objective was to use DCA to evaluate clinical usefulness of combining
55
56
57
58
59
60

1
2
3
4
5
6 serum CRP levels to the CURB-65 score in patients with suspected sepsis, regardless of
7
8
9 the source of infection.
10

11 **Materials and Methods**

12 *Study Design, Setting and Patients*

13
14
15 We performed a retrospective cohort study at Kyoto City Hospital, an urban teaching
16
17 hospital with 548 beds in Japan. Consecutive emergency department (ED) patients over
18
19 15 years old admitted to the hospital after having a blood culture taken in the ED
20
21 between 1 January 2010 and 31 December 2012 were included. Doctors' decision to
22
23 order a blood culture was used as a surrogate marker for suspected sepsis as in previous
24
25 studies.^{11 23} To facilitate data independence, only the index admission was included for
26
27 patients with multiple admissions during the study period. Patients transferred from
28
29 another hospital or who had cardiopulmonary arrest on arrival at the hospital were
30
31 excluded.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 *Data collection*

54
55
56 The following data were extracted from electronic medical records for each patient: age,
57
58
59
60

1
2
3
4
5
6 gender, underlying disease, vital signs (heart rate, blood pressure, respiratory rate, and
7
8
9 mental confusion and body temperature), laboratory findings (white blood cell [WBC]
10
11
12 count, platelet count, and blood urea nitrogen [BUN] and serum CRP levels), and
13
14
15 outcome. For vital signs and laboratory data, initial values at the hospital visit were
16
17
18 recorded. Blood pressure was measured with noninvasive cuff. Serum CRP was
19
20
21 measured with latex turbidimetric immunoassay. The items of the CURB-65 score were
22
23
24 as follows: mental confusion (present/absent), BUN > 7 mmol/L (20 mg/dL),
25
26
27 respiratory rate (RR) \geq 30/min, either or both systolic blood pressure (SBP) < 90 mmHg
28
29
30 or diastolic blood pressure (DBP) \leq 60 mmHg, and age \geq 65 years.⁶ Mental confusion
31
32
33 was defined as disorientation in person, place or time or being in a stupor or coma as
34
35
36 with a previous study.⁶
37
38
39
40

41
42 The main outcome measure was 30-day in-hospital mortality. Patients who were
43
44
45 discharged or transferred from the hospital within 30 days of admission or who
46
47
48 remained in the hospital for more than 30 days were considered alive in this analysis.²⁴
49
50
51
52
53

54 *Statistical analysis*

55
56
57
58
59
60

1
2
3
4
5
6 First, we validated the CURB-65 model. We graphically assessed the calibration of the
7
8
9
10 CURB-65 model with calibration plot and tested it with the Hosmer-Lemeshow test. A p
11
12
13 value < 0.05 indicates a lack of good fit for the model. Regarding the model
14
15
16 discrimination, we also computed the area under the receiver operating characteristic
17
18
19 curve (AUC) with a 95% confidence interval (CI) using 500 bootstrap resampling.²⁵
20
21
22 The predicted mortalities with 95% CI were calculated by introducing the CURB-65
23
24
25 score as a continuous variable into univariable logistic regression.
26
27

28
29 Second, we examined additional value of serum CRP. We graphically checked
30
31
32 whether or not the relationship between serum CRP level and mortality was linear in the
33
34
35 logit with a smoothing curve using a locally weighted least squares (Lowess)
36
37
38 regression.²⁶ We conducted logistic regression analysis after adding CRP as a
39
40
41 continuous variable to the CURB-65 system. User-friendliness is important for clinical
42
43
44 prediction rules and dichotomized test results (normal vs abnormal) are easy to use and
45
46
47 interpret. We explored the cut-off point of serum CRP level for prediction of death in
48
49
50 patients with suspected sepsis because the optimal cut-off point was unknown. Serum
51
52
53
54
55 CRP results were first divided into quartiles and rounded to the nearest 10. Each patient
56
57
58
59
60

1
2
3
4
5
6 was then assigned to one of four categories corresponding to the CRP quartiles. We
7
8
9
10 assessed the most optimal cut-off point from the AUC. We conducted multivariable
11
12
13 logistic regression analysis to adjust predictors of death by introducing pre-specified
14
15
16 variables: items of the CURB-65. We assessed multicollinearity using the variance
17
18
19 inflation factor (VIF). VIFs greater than 2.5 may be problematic.²⁷ We also computed
20
21
22 the unadjusted odds ratio of covariates using univariable logistic regression to show the
23
24
25 influence of adjustment for predictors.
26
27

28
29 Third, we assessed the model performance of the modified CURB-65 score,
30
31
32 which was made by incorporating CRP information into the CURB-65 model, using a
33
34
35 calibration plot and Hosmer-Lemeshow test for calibration and AUC for discrimination.
36
37
38 Additive information of CRP was evaluated by category-free NRI and IDI.²⁸ With
39
40
41 regard to clinical usefulness, we examined the net benefit using DCA.²² Briefly, the
42
43
44 method is based on the principle that the relative harms of false positives and false
45
46
47 negatives can be expressed in terms of a probability threshold.²⁹ The net benefit is
48
49
50 obtained by subtracting the proportion of patients who are false positive from the
51
52
53 proportion who are true positive, weighting by the relative harm of a false-positive and
54
55
56
57
58
59
60

1
2
3
4
5
6 a false-negative result. The net benefit of making a decision based on the model can be
7
8
9
10 calculated with the following formula:

$$\text{Net benefit} = \frac{\text{True Positives}}{n} - \left(\frac{P_t}{1-P_t}\right) \frac{\text{False positives}}{n}$$

11
12
13
14
15
16
17
18
19
20
21
22 where n is the total number of patients in the study and P_t is a given threshold
23
24
25 probability.^{22 29 30}

26
27
28
29 With regard to sample size estimation, at least 8 to 10 events per variable are
30
31
32 required for reliable multiple logistic regression analysis,^{31 32} and 100 events and 100
33
34
35 nonevents are required for an external validation study.³³ We assumed 30 to 40 deaths
36
37
38 per year among eligible patients, collecting 3 years' worth of data (90 to 120 estimated
39
40
41
42 deaths) to appropriately conduct multiple logistic regressions with 11 variables and
43
44
45 ensure adequate statistical power.

46
47
48 In terms of handling missing values, we planned to perform a complete case
49
50
51 analysis if missing values were below 5%, as such an analysis might be feasible then.³⁴

52
53
54
55 If missing values were above 5%, we planned to apply an appropriate imputation

1
2
3
4
5
6 method.

7
8
9 Data were analyzed with R software 3.0.1 (www.r-project.org) and Stata software,
10 version 13 (StataCorp., College Station, TX, USA) including programs of Decision
11 Curve Analysis provided by Vickers.³⁵
12
13
14
15
16
17
18
19

20 21 22 *Ethical approval*

23
24 This protocol was approved by the Ethics Committee of Kyoto University Graduate
25 School and Faculty of Medicine and Kyoto City Hospital.
26
27
28
29
30
31
32
33

34 **Results**

35 36 *Patient characteristics*

37
38 Among 1310 eligible patients over 3 years of study, 108 deaths (8.2% mortality) were
39 recorded. Demographics, underlying diseases, vital signs, laboratory findings and chief
40 diagnosis for admission were presented in Table 1. Diagnosis was unclear in 92 patients
41 (7.3%). Respiratory rates data were missing for 21 patients, and CRP data were missing
42 for 28 (Table 3). Overall cases with any missing predictor were 48 (3.7%), so we
43 conducted a complete case analysis, leaving 1262 patients (106 deaths, 8.4% mortality)
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 for model evaluation analyses.
7
8
9

10 11 12 *Validation of the CURB-65 in our population* 13

14
15
16 Observed 30-day in-hospital mortalities and predicted mortalities computed by the
17
18 CURB-65 score are shown in Table 4. The CURB-65 showed good calibration for
19
20 mortality, with a Hosmer-Lemeshow test of 4.08 (df=5, P=0.538), indicating good fit.
21
22 The calibration plot is shown in Supplementary Figure 1a. The AUC for the CURB-65
23
24 was 0.76 (95% CI: 0.72 to 0.80; Supplementary Figure 2).
25
26
27
28
29
30
31
32
33
34

35 *Evaluation of CRP as a predictor of mortality* 36

37
38 The relationship between serum CRP level and mortality was almost linear in the logit
39
40 (Supplementary Figure 3). An unadjusted odds ratio for mortality was 1.05 (95% CI:
41
42 1.03 to 1.07) per 10 mg/L rise in serum CRP level. Addition of continuous serum CRP
43
44 level to the CURB-65 system revealed an adjusted odds ratio for mortality was 1.04
45
46
47
48
49 (95% CI: 1.01 to 1.06) per 10 mg/L increase in concentration. Because the optimal
50
51
52
53
54
55 cut-off point was unknown, serum CRP results were divided into quartiles: the quartile
56
57
58
59
60

1
2
3
4
5
6 points were 18.2, 72.3 and 149.2 mg/L. Then, they were rounded to the nearest 10, and
7
8
9 we set interim cut-off points as 20, 70, and 150 mg/L. Observed mortality and
10
11 unadjusted odds ratios for mortality of each CRP group are shown in Table 2. We
12
13 repeated regression analyses adding serum CRP as a dichotomized variable with each
14
15 interim cut-off point. We found 150 mg/L as the most optimal threshold to dichotomize
16
17
18
19
20
21
22 serum CRP levels.
23

24
25
26 Adjusted odds ratios for mortality are shown in Table 3. We found no evidence of
27
28 multicollinearity because the variance inflation factors for predictors in the model in
29
30 Table 3 were less than 1.2. We identified serum CRP level ≥ 150 mg/L as an
31
32 independent predictor of death in patients with clinically suspected sepsis.
33
34
35
36
37
38
39
40
41
42
43
44

45 *Additive information of CRP to CURB-65*

46
47 Because the adjusted odds ratio (i.e. regression coefficient) of CRP was comparable to
48
49 each item in the CURB-65, we made a modified CURB-65 score by adding one point to
50
51
52 the CURB-65 score when serum CRP level was ≥ 150 mg/L. Table 4 shows observed
53
54
55
56
57
58
59
60

1
2
3
4
5
6 30-day in-hospital mortalities and predicted mortalities stratified by the modified
7
8
9
10 CURB-65 score. The modified CURB-65 also showed good calibration for mortality,
11
12 with a Hosmer-Lemeshow test of 4.52 (df=6, P=0.607). The calibration plot is shown in
13
14
15
16 Supplementary Figure 1b. The AUC for the modified CURB-65 was 0.77 (95% CI: 0.72
17
18 to 0.81; Supplementary Figure 2). By incorporating CRP into CURB-65, event NRI was
19
20 -0.151 and nonevent NRI was 0.538, giving an overall category-free NRI of 0.387
21
22 (95% CI: 0.193 to 0.582, p<0.0001). Further, IDI for events was 0.014 and IDI for
23
24 nonevents was 0.001, giving an overall IDI of 0.015 (95% CI: 0.004 to 0.027, p<0.01).
25
26
27
28
29
30
31
32 These findings were statistically significant.
33
34
35
36
37
38
39

40 *Decision curve analysis*

41
42 Figure 1 demonstrates the decision curves for the CURB-65 and modified CURB-65 to
43
44 predict 30-day in-hospital mortality in patients with clinically suspected sepsis. Both the
45
46 CURB-65 and the modified CURB-65 are useful between threshold probabilities of 0%
47
48 to 30%. However, both curves cross and depict little difference in net benefit. The net
49
50 benefits at each point of the CURB-65 score and the modified CURB-65 score are
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 shown in Table 4. The comparison of discrimination, calibration, reclassification
7
8
9 metrics and clinical usefulness between CURB-65 and modified CURB-65 are
10
11
12 summarized in Table 5.
13

14
15
16 To assess the robustness of our findings, we repeated DCA with changing the
17
18 cut-off level of serum CRP as 20 mg/L and 70 mg/L, respectively, in sensitivity analyses.
19

20
21
22 Similarly, we found the additive clinical usefulness of serum CRP was unremarkable.
23
24
25
26
27
28
29

30 31 **Discussion**

32
33 We determined that having high CRP levels was independently associated with high
34
35 mortality in our population. We also confirmed geographical and domain validation of
36
37 the CURB-65 in our patients, which comprised an external validation in a different
38
39 geographical area and in a population including different category of patients from
40
41
42
43
44
45
46
47 CAP.⁴

48
49
50 The utility of serum CRP as a prognostic marker has been found to vary.¹² In
51
52
53 Japan, universal health coverage allows people to consult a doctor soon after they
54
55
56 recognize any symptoms, with no particular limitations.³⁶ Given that secretion of CRP
57
58
59
60

1
2
3
4
5
6 peaks at 36-50 h after inflammatory stimulus,¹² serum CRP level might be useful as a
7
8
9 surrogate marker of duration from disease onset to consulting a doctor as well as a
10
11
12 marker reflecting intensity of inflammation. We believe that the association between
13
14
15 serum CRP level and mortality will be more easily identified in countries such as Japan
16
17
18 where the population has easy access to hospitals, due to the wide distribution in
19
20
21 duration from disease onset to visiting a hospital. Although reclassification metrics such
22
23
24 as NRI and IDI were statistically improved on incorporation of CRP level, the additive
25
26
27 clinical usefulness of CRP to the CURB-65 was admittedly limited (Table 5).
28
29
30
31
32
33
34

35 **Strengths and limitations of the study**

36
37
38 A major strength of this study is our evaluation using DCA. To the best of our
39
40
41 knowledge, this is the first study, which examined clinical usefulness of serum CRP and
42
43
44 the CURB-65 score in septic patients using DCA. DCA can take into account risk
45
46
47 threshold, weighting benefits and harms, and is useful in evaluating clinical utility of a
48
49
50 prediction model.^{21 22 37} For instance, the net benefit of 0.061 at a threshold probability
51
52
53 of 3% in the CURB-65 score can be interpreted as meaning that making a decision
54
55
56
57
58
59
60

1
2
3
4
5
6 based on the prediction model, compared to assuming that all patients would be alive,
7
8
9
10 leads to the equivalent of a net 6.1 true-positive results per 100 patients with no
11
12
13 corresponding increase in the number of false-positive results (Table 4).²² In our
14
15
16 population, 8.4% overall 30-day in-hospital mortality means a maximum net benefit of
17
18
19 0.084, which is calculated if we use a threshold probability of 0%. There are no
20
21
22 universally accepted criteria on patient's risk threshold for suspected sepsis to make a
23
24
25 decision about patient disposition or therapeutic indication. If we extrapolate the data on
26
27
28 community-acquired pneumonia, low, intermediate and high risk of mortality are
29
30
31 considered to be about 1-2%, 8-9% and 20-30%, respectively.⁶ The ability to make
32
33
34 better decisions with serum CRP than without was considered to be unremarkable in
35
36
37 this range of risk threshold.
38
39

40
41
42 Our study is a type of external validation study with model updating to assess
43
44
45 whether serum CRP level has additive value to the CURB-65 or not.⁴ Another strengths
46
47
48 of this study might be our sample size with adequate statistical power for an external
49
50
51 validation study.³³
52

53
54
55 Several limitations to the present study warrant mention. We cannot rule out the
56
57
58
59
60

1
2
3
4
5
6 possibility of selection bias, as only inpatients who had a blood culture taken were
7
8
9 included. We may therefore have missed patients with infection who did not undergo
10
11
12 blood culture in the ED, and contrarily, some patients without infection were included in
13
14
15 the study. However, clinicians must routinely make decisions in the ED despite being
16
17
18 unsure as to whether or not a patient is actually infected; we therefore considered it
19
20
21 important to evaluate a clinical prediction rule accounting for such clinical uncertainty.
22
23
24 Inclusion of patients without infectious diseases, we feel, reflects a real-world scenario.
25
26
27
28 Another limitation is the retrospective nature of the study and the fact that it was
29
30
31 conducted in a single hospital. Given the study's retrospective design, patients with high
32
33
34 CRP might have received more intensive therapy than those with relatively low CRP.
35
36
37
38 Such bias might have lowered the predictive ability of CRP.
39
40
41
42
43
44
45
46
47

48 **Conclusions**

49
50
51 While serum CRP level ≥ 150 mg/L was found to be associated with high mortality, its
52
53
54 additive clinical usefulness to the CURB-65 was limited based on DCA. The CURB-65
55
56
57
58
59
60

1
2
3
4
5
6 correlated well with 30-day in-hospital mortality in patients with clinically suspected
7
8
9 infection, and it was useful among threshold probabilities in the range of 0% to 30%.
10
11
12 Measurement of serum CRP may contribute little to making decisions regarding the
13
14 management of clinically suspected sepsis patients.
15
16
17
18
19
20
21
22
23
24
25
26

27 **Contributors**

28
29
30 S. Yamamoto had full access to all of the data in the study and takes responsibility for
31
32 integrity of the data and accuracy of the data analysis and wrote the first draft.
33
34

35
36
37 T. Shimizu, K. Tochitani, Y. Tsuchido and K. Shinohara collected and interpreted the
38
39 data, and drafted the paper.
40
41

42
43 S. Yamazaki, T. Takeshima, S. Fukuma, Y. Yamamoto and S. Fukuhara supervised the
44
45 research, interpreted the data and contributed to the writing of the manuscript.
46
47
48
49
50
51

52 **Funding**

53
54
55
56 This research received no specific grant from any funding agency in the public,
57
58
59
60

1
2
3
4
5
6 commercial or not-for-profit sectors.
7
8
9

10 11 12 13 **Competing interests**

14
15
16 None.
17
18
19

20 21 22 **Ethics approval**

23
24 The Ethics Committee of Kyoto University Graduate School and Faculty of Medicine
25
26 and Kyoto City Hospital.
27
28
29
30
31
32
33
34

35 **Data sharing statement**

36
37
38 No additional data are available.
39
40
41
42
43
44
45
46
47
48
49
50

51 **References**

52
53
54 1. Kumar G, Kumar N, Taneja A, et al. Nationwide trends of severe sepsis in the 21st
55
56
57
58
59
60

- 1
2
3
4
5
6 century (2000-2007). *Chest* 2011;**140**:1223-31.
- 7
8
9
10 2. Kaukonen K-M, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and
11
12 septic shock among critically ill patients in Australia and New Zealand,
13
14 2000-2012. *JAMA* 2014;**311**:1308-16.
- 15
16
17
18 3. Fujishima S, Gando S, Saitoh D, et al. A multicenter, prospective evaluation of
19
20 quality of care and mortality in Japan based on the Surviving Sepsis Campaign
21
22 guidelines. *Journal of infection and chemotherapy* 2014;**20**:115-20.
- 23
24
25
26
27
28 4. Toll DB, Janssen KJM, Vergouwe Y, et al. Validation, updating and impact of clinical
29
30 prediction rules: a review. *Journal of clinical epidemiology* 2008;**61**:1085-94.
- 31
32
33
34 5. Calle P, Cerro L, Valencia J, et al. Usefulness of severity scores in patients with
35
36 suspected infection in the emergency department: a systematic review. *The*
37
38 *Journal of emergency medicine* 2012;**42**:379-91.
- 39
40
41
42
43
44 6. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired
45
46 pneumonia severity on presentation to hospital: an international derivation and
47
48 validation study. *Thorax* 2003;**58**:377-82.
- 49
50
51
52
53
54 7. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for
55
56
57
58
59
60

- 1
2
3
4
5
6 predicting mortality in hospitalised patients with community-acquired
7
8
9 pneumonia. Systematic review and meta-analysis. *Thorax* 2010;**65**:878-83.
10
11
12
13 8. Chalmers JD, Singanayagam A, Akram AR, et al. Safety and efficacy of
14
15 CURB65-guided antibiotic therapy in community-acquired pneumonia. *Journal*
16
17
18
19
20 of Antimicrobial Chemotherapy 2011;**66**:416-23.
21
22
23 9. Howell MD, Donnino MW, Talmor D, et al. Performance of severity of illness
24
25
26
27
28
29
30
31 scoring systems in emergency department patients with infection. *Academic*
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10. Armiñanzas C, Velasco L, Calvo N, et al. CURB-65 as an initial prognostic score in
Internal Medicine patients. *European journal of internal medicine*
2013;**24**:416-19.
11. Marwick CA, Guthrie B, Pringle JE, et al. Identifying which septic patients have
increased mortality risk using severity scores: a cohort study. *BMC*
anesthesiology 2014;**14**:1.
12. Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious
systemic inflammatory response syndrome. *Clinica chimica acta*

2005;**351**:17-29.

13. Saito A, Miki F, Oizumi K, et al. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy. *Journal of infection and chemotherapy* 1999;**5**:110-23.
14. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. *The American journal of medicine* 2008;**121**:219-25.
15. Lobo SMA, Lobo FRM, Bota DP, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. *Chest* 2003;**123**:2043-49.
16. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clinical infectious diseases* 2004;**39**:206-17.
17. van Vugt SF, Broekhuizen BDL, Lammens C, et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic

- 1
2
3
4
5
6 study. *BMJ* 2013;**346**:f2450-f50.
7
8
9
10 18. Holmberg L, Vickers A. Evaluation of prediction models for decision-making:
11
12 beyond calibration and discrimination. *PLoS Medicine* 2013;**10**:e1001491.
13
14
15
16 19. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of
17
18 prediction models: a framework for traditional and novel measures.
19
20
21 *Epidemiology (Cambridge, Mass)* 2010;**21**:128-38.
22
23
24
25 20. Leening MJG, Vedder MM, Witteman JCM, et al. Net reclassification improvement:
26
27 computation, interpretation, and controversies: a literature review and clinician's
28
29 guide. *Annals of internal medicine* 2014;**160**:122-31.
30
31
32
33
34
35 21. Vickers AJ, Pepe M. Does the net reclassification improvement help us evaluate
36
37 models and markers? *Annals of internal medicine* 2014;**160**:136-37.
38
39
40
41
42 22. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating
43
44 prediction models. *Medical decision making* 2006;**26**:565-74.
45
46
47
48 23. Shapiro NI, Wolfe RE, Moore RB, et al. Mortality in Emergency Department Sepsis
49
50 (MEDS) score: a prospectively derived and validated clinical prediction rule.
51
52
53
54
55 *Critical Care Medicine* 2003;**31**:670-75.
56
57
58
59
60

- 1
2
3
4
5
6 24. Graham PL, Cook DA. Prediction of risk of death using 30-day outcome: a practical
7
8
9
10 end point for quality auditing in intensive care. *Chest* 2004;**125**:1458-66.
11
12 25. Steyerberg EW, Bleeker SE, Moll HA, et al. Internal and external validation of
13
14
15 predictive models: a simulation study of bias and precision in small samples.
16
17
18
19 *Journal of clinical epidemiology* 2003;**56**:441-47.
20
21
22 26. Hosmer DW. 4 Independent variables in multivariable analysis. *Applied Logistic*
23
24
25
26
27 Regression. 3 ed. Hoboken, New Jersey: Wiley, 2013.
28
29 27. Katz MH. *Multivariable Analysis: A Practical Guide for Clinicians and Public*
30
31
32
33
34 *Health Researchers*. 3rd ed. New York: Cambridge University Press, 2011.
35
36 28. Cook NR, Paynter NP. Performance of reclassification statistics in comparing risk
37
38
39
40 prediction models. *Biometrical journal* 2011;**53**:237-58.
41
42 29. Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a
43
44
45
46
47
48 novel method for evaluating diagnostic tests, prediction models and molecular
49
50
51
52
53
54
55
56
57
58
59
60 markers. *BMC medical informatics and decision making* 2008;**8**:53.
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

- 1
2
3
4
5
6 31. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events
7
8
9 per variable in logistic regression analysis. *Journal of clinical epidemiology*
10
11
12 1996;**49**:1373-79.
13
14
15
16 32. Cepeda MS, Boston R, Farrar JT, et al. Comparison of logistic regression versus
17
18 propensity score when the number of events is low and there are multiple
19
20 confounders. *American journal of epidemiology* 2003;**158**:280-87.
21
22
23
24
25 33. Vergouwe Y, Steyerberg EW, Eijkemans MJC, et al. Substantial effective sample
26
27 sizes were required for external validation studies of predictive logistic
28
29 regression models. *Journal of clinical epidemiology* 2005;**58**:475-83.
30
31
32
33
34
35 34. Royston P, Moons KGM, Altman DG, et al. Prognosis and prognostic research:
36
37 Developing a prognostic model. *BMJ* 2009;**338**:b604.
38
39
40
41
42 35. Vickers AJ. Decision Curve Analysis. *Secondary Decision Curve Analysis*. 2013.
43
44
45 [http://www.mskcc.org/research/epidemiology-biostatistics/health-outcomes/decision-cu](http://www.mskcc.org/research/epidemiology-biostatistics/health-outcomes/decision-curve-analysis-0)
46
47 [rve-analysis-0](http://www.mskcc.org/research/epidemiology-biostatistics/health-outcomes/decision-curve-analysis-0). Accessed 19 April, 2014.
48
49
50
51 36. Ikegami N, Yoo B-K, Hashimoto H, et al. Japanese universal health coverage:
52
53 evolution, achievements, and challenges. *Lancet* 2011;**378**:1106-15.
54
55
56
57
58
59
60

- 1
2
3
4
5
6 37. Localio AR, Goodman S. Beyond the usual prediction accuracy metrics: reporting
7
8
9 results for clinical decision making. *Annals of internal medicine*
10
11
12 2012;**157**:294-95.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Patient characteristics, chief diagnosis for admission, and outcome

Characteristics	n=1262
Demographics	
<i>Age (years), median (IQR)</i>	76 (64-83)
<i>Female, n (%)</i>	560 (44.4)
<i>Nursing home resident, n (%)</i>	37 (2.9)
Underlying diseases, n (%)	
<i>Cerebrovascular disease</i>	156 (12.4)
<i>Congestive heart failure</i>	101 (8.0)
<i>Chronic respiratory disease</i>	155 (12.3)
<i>Chronic kidney disease</i>	100 (7.9)
<i>Chronic liver disease</i>	77 (6.1)
<i>Diabetes mellitus</i>	243 (19.3)
<i>Malignancy</i>	222 (17.6)
<i>Dementia</i>	121 (9.6)
<i>Autoimmune disorder</i>	63 (5.0)
<i>Human immunodeficiency virus positive</i>	3 (0.2)
Vital signs	
<i>Heart rate (beats/min), median (IQR)</i>	98 (85-156)
<i>Systolic blood pressure (mmHg), median (IQR)</i>	131 (113-150)
<i>Respiratory rate (breaths/min), median (IQR)</i>	20 (18-24)
<i>Body temperature (°C), median (IQR)</i>	38.1 (37.1-39)
<i>Mental confusion, n (%)</i>	215 (17.0)
Laboratory data	
<i>White blood cell count (10⁹/L), median (IQR)</i>	10.5 (7.6-14.6)
<i>Platelet count (×10⁹/L), median (IQR)</i>	196 (150-256)
<i>C reactive protein (mg/L), median (IQR)</i>	72.3 (18.2-149.2)
<i>Blood urea nitrogen (mmol/L), median (IQR)</i>	6.9 (5.0-10.2)
Chief diagnosis for admission	
<i>Pneumonia</i>	393 (33.6)
<i>Urinary tract infection</i>	188 (16.1)
<i>Skin and Soft tissue infection</i>	62 (5.3)

<i>Acute cholangitis</i>	47 (4.0)
<i>Acute cholecystitis</i>	33 (2.8)
<i>Bowel perforation</i>	21 (1.8)
<i>Other bacterial infection</i>	150 (12.8)
<i>Non-bacterial infection</i>	103 (8.8)
<i>Non-infection</i>	174 (14.9)
<i>Unclear</i>	92 (7.3)
Bacteremia, n (%)	210 (16.6)
30-day in-hospital mortality, n (%)	106 (8.4)

Abbreviation: IQR, interquartile range

peer review only

Table 2. Observed mortality and unadjusted odds ratios for mortality stratified by serum CRP categories

Variables	Observed 30-day mortality, % (death/total)	Unadjusted Odds Ratio* (95% CI)
CRP		
<i>0.1-19.9 mg/L</i>	4.0 (13/326)	1 [reference]
<i>20-69.9 mg/L</i>	6.6 (19/289)	1.7 (0.8-3.5)
<i>70-149.9 mg/L</i>	8.7 (29/335)	2.3 (1.2-4.5)
<i>≥ 150 mg/L</i>	14.4 (45/312)	4.1 (2.1-7.7)

Abbreviation: CRP, C reactive protein

*Calculated by univariable logistic regression

Table 3. Adjusted odds ratios for mortality in multivariable logistic regression analyses

Variables	Unadjusted Odds Ratios (95% CI)	Adjusted Odds Ratios* (95% CI)	Missing n, (%)
CRP \geq 150 mg/L	2.5 (1.6-3.7)	2.0 (1.3-3.1)	28 (2.1)
Age \geq 65 years	3.7 (1.9-7.3)	2.3 (1.1-4.6)	0 (0)
Mental confusion	2.9 (1.9-4.5)	2.1 (1.3-3.4)	0 (0)
Hypotension (SBP < 90 or DBP \leq 60 mmHg)	3.0 (2.0-4.5)	2.1 (1.3-3.2)	0 (0)
Tachypnea (RR \geq 30/min)	3.1 (2.0-4.8)	2.4 (1.5-3.9)	21 (1.6)
BUN > 7 mmol/L	4.7 (2.9-7.6)	2.7 (1.6-4.5)	0 (0)
Overall	-	-	48 (3.7)

Abbreviation: CRP, C reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; RR, respiratory rate; BUN, blood urea nitrogen

*Adjusted for items of the CURB-65

Table 4. Observed mortality, predicted mortality, and net benefit in the CURB-65 and the modified CURB-65*

CURB-65 score	Observed 30-day mortality, % (death/total)	Predicted mortality [†] (95% CI) %	Net benefit [‡]	Modified CURB-65 score	Observed 30-day mortality, % (death/total)	Predicted mortality [†] (95% CI) %	Net benefit [‡]
0	0 (0/190)	1 (0.7-2.1)	0.075	0	0 (0/152)	1 (0.6-2.0)	0.075
1	3 (9/334)	3 (2.0-4.2)	0.061	1	2 (7/287)	2 (1.6-3.6)	0.068
2	8 (33/409)	7 (5.2-8.3)	0.034	2	6 (23/381)	5 (4.0-6.9)	0.048
3	13 (34/254)	14 (11.9-17.2)	0.015	3	12 (32/265)	11 (9.2-13.3)	0.024
4	30 (25/84)	28 (22.5-35.2)	0.004	4	17 (22/129)	22 (17.7-26.5)	0.012
5	39 (7/18)	48 (37.0-60.1)	0	5	44 (18/41)	38 (29.9-47.8)	0.005
				6	57 (4/7)	58 (45.2-70.4)	0

* The modified CURB-65 score was made by addition of 1 point if CRP \geq 150 mg/L.

† Predicted mortality was calculated by introducing the CURB-65 and modified CURB-65 score as a continuous variable into univariable logistic regression.

‡ Net benefits were calculated for each predicted mortality as a threshold probability.


Table 5. Comparison of discrimination, calibration, reclassification metrics and clinical usefulness between CURB-65 and modified CURB-65

	CURB-65	Modified CURB-65
Discrimination		
AUC	0.76 (95% CI: 0.72 to 0.80)	0.77 (95% CI: 0.72 to 0.81)
Calibration		
Hosmer-Lemeshow test and calibration plot	good	good
Reclassification		
Overall category-free NRI	0.387 (95% CI: 0.193 to 0.582, p<0.0001)	
Overall IDI	0.015 (95% CI: 0.004 to 0.027, p<0.01)	
Clinical usefulness		
NB examined by DCA	comparable	

Abbreviation: AUC, area under the receiver operating characteristic curve; NRI, net reclassification improvement; IDI, integrated discrimination improvement; NB, net benefit; DCA, decision curve analysis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1. Decision curves for the CURB-65 and modified CURB-65 (mCURB-65) to predict 30-day mortality in patients with suspected sepsis



The thick black line is the net benefit of treating no patients, assuming that all would be alive; the thin grey line is the net benefit of treating all patients similarly regardless of their severity, assuming that all would die; the long dashed line is the net benefit of treating patients according to the CURB-65 score; and the thin black line is the net benefit of treating patients based on the modified CURB-65 score.

209x297mm (300 x 300 DPI)

Supplementary Figure 1a. Calibration plot of the CURB-65




209x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure 1b. Calibration plot of the modified CURB-65



209x297mm (300 x 300 DPI)

Supplementary Figure 2. The receiver operating characteristics curves of the CURB-65 and the modified CURB-65




209x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure 3. The relationship between serum CRP level and mortality; locally weighted scatterplot smoothing (Lowess) curve



209x297mm (300 x 300 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract [Within the method section of the abstract page 3] (b) Provide in the abstract an informative and balanced summary of what was done and what was found [See results section of abstract page 3-4]
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported [page 5-7]
Objectives	3	State specific objectives, including any prespecified hypotheses [page 7]
Methods		
Study design	4	Present key elements of study design early in the paper [Methods page 6]
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection [Methods page 6-7]
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up [Methods page 6-7] <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls [N/A] <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants [N/A] (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed [N/A] <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case [N/A]
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable [page 7]
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group [page 7]
Bias	9	Describe any efforts to address potential sources of bias [page 6-7]
Study size	10	Explain how the study size was arrived at [page 10]
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why [page 7-8]
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding [page 7-9] (b) Describe any methods used to examine subgroups and interactions [N/A] (c) Explain how missing data were addressed [page 11] (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed [page 7-8] <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed [N/A] <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy [N/A] (e) Describe any sensitivity analyses [N/A]

Continued on next page

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed [page 11 and table 1] (b) Give reasons for non-participation at each stage [N/A] (c) Consider use of a flow diagram [N/A information in page 11 and table 1]
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders [page 11 and table 1] (b) Indicate number of participants with missing data for each variable of interest [table 3] (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount) [page 11]
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time [page 11 and table 1] <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure [N/A] <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures [N/A]
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included [page 11-13; table 2 and 3] (b) Report category boundaries when continuous variables were categorized [page 11-12; table 2] (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period [N/A]
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses [decision curve analysis in page 13; table 4; figure 1]
Discussion		
Key results	18	Summarise key results with reference to study objectives [page 13-14]
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias [page 15-16]
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence [page 14-16]
Generalisability	21	Discuss the generalisability (external validity) of the study results [page 15]
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based [N/A]

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.